Cystatin C and cardiovascular mortality in patients with coronary artery disease and normal or mildly reduced kidney function: Results from the AtheroGene study

European Heart Journal

Volumn 30, Issue 3, 2009, Pages 314-320

  Keller, Till ^a   Messow, Claudia Martina ^a   Lubos, Edith ^a   Nicaud, Viviane ^b,c   Wild, Philipp S ^a   Rupprecht, Hans J ^d   Bickel, Christoph ^e   Tzikas, Stergios ^a   Peetz, Dirk ^a   Lackner, Karl J ^a   Tiret, Laurence ^b,c   Münzel, Thomas F ^a   Blankenberg, Stefan ^a   Schnabel, Renate B ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b INSERM   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d Klinik für Geburtshilfe und Frauenkrankheiten   (Germany)

^e BUNDESWEHRZENTRALKRANKENHAUS KOBLENZ   (Germany)

Author keywords

Cardiovascular mortality; Coronary artery disease; Cystatin C; Risk stratification

Indexed keywords

ACETYLSALICYLIC ACID; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; CREATININE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CAUSE OF DEATH; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HAZARD RATIO; HUMAN; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CORONARY ARTERY DISEASE; CYSTATIN C; FEMALE; GERMANY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 59749086035     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehn598     Document Type: Article

References (40)

1. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol 2002;13:745-753.
2. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis 2003;42:677-864.
3. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol 2003;41:47-55.
4. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97.
5. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004;351:1296-1305.
6. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003;108:2154-2169.
7. McCullough PA, Soman SS, Shah SS, Smith ST, Marks KR, Yee J, Borzak S. Risks associated with renal dysfunction in patients in the coronary care unit. J Am Coll Cardiol 2000;36:679-684.
8. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-689.
9. Shlipak MG, Simon JA, Grady D, Lin F, Wenger NK, Furberg CD. Renal insufficiency and cardiovascular events in postmenopausal women with coronary heart disease. J Am Coll Cardiol 2001;38:705-711.
10. Shlipak MG, Heidenreich PA, Noguchi H, Chertow GM, Browner WS, McClellan MB. Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients. Ann Intern Med 2002;137:555-562.
11. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol 2007;27:197-205.
12. Pucci L, Triscornia S, Lucchesi D, Fotino C, Pellegrini G, Pardini E, Miccoli R, Del Prato S, Penno G. Cystatin C and estimates of renal function: searching for a better measure of kidney function in diabetic patients. Clin Chem 2007;53:480-488.
13. Ix JH, Shlipak MG, Chertow GM, Whooley MA. Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 2007;115:173-179.
14. Koenig W, Twardella D, Brenner H, Rothenbacher D. Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 2005;51:321-327.
15. Jernberg T, Lindahl B, James S, Larsson A, Hansson LO, Wallentin L. Cystatin C: a novel predictor of outcome in suspected or confirmed non-ST-elevation acute coronary syndrome. Circulation 2004;110:2342-2348.
16. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699-707.
17. Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS. Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 2007;28:1841-1847.
18. Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666-675.
19. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J, Munzel T, Cambien F, Tiret L, Blankenberg S. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005;26:241-249.
20. Blankenberg S, Rupprecht HJ, Bickel C, Torzewski M, Hafner G, Tiret L, Smieja M, Cambien F, Meyer J, Lackner KJ. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N Engl J Med 2003;349:1605-1613.
21. R Development Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2005. ISBN 3-900051-07-0, URL http://www.R-project.org.
22. Codognotto M, Piccoli A, Zaninotto M, Mion M, Vertolli U, Tona F, Boffa GM. Cystatin C in heart failure is nothing more than a bystander of glomerular filtration. J Nephrol 2007;20:219-227.
23. Shlipak MG, Sarnak MJ, Katz R, Fried LF, Seliger SL, Newman AB, Siscovick DS, Stehman-Breen C. Cystatin C and the risk of death and cardiovascular events among elderly persons. N Engl J Med 2005;352:2049-2060.
24. Rigalleau V, Raffaitin C, Gin H, Beauvieux MC, Le Moigne F, Lasseur C, Chauveau P, Combe C, Barthe N. Accounting for body composition does not improve cystatin C estimation of GFR in diabetic subjects with CKD. Am J Kidney Dis 2007;49:560 (author reply 561).
25. Fliser D, Ritz E. Serum cystatin C concentration as a marker of renal dysfunction in the elderly. Am J Kidney Dis 2001;37:79-83.
26. Keevil BG, Kilpatrick ES, Nichols SP, Maylor PW. Biological variation of cystatin C: implications for the assessment of glomerular filtration rate. Clin Chem 1998;44:1535-1539.
27. Keller CR, Odden MC, Fried LF, Newman AB, Angleman S, Green CA, Cummings SR, Harris TB, Shlipak MG. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the health, aging, and body composition study. Kidney Int 2007;71:239-244.
28. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 1996;93:1963-1969.
29. Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann M, Riegger GA, Schunkert H, Holmer S. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002;39:99-104.
30. Austin WJ, Bhalla V, Hernandez-Arce I, Isakson SR, Beede J, Clopton P, Maisel AS, Fitzgerald RL. Correlation and prognostic utility of B-type natriuretic peptide and its amino-terminal fragment in patients with chronic kidney disease. Am J Clin Pathol 2006;126:506-512.
31. Blankenberg S, McQueen MJ, Smieja M, Pogue J, Balion C, Lonn E, Rupprecht HJ, Bickel C, Tiret L, Cambien F, Gerstein H, Munzel T, Yusuf S. Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. Circulation 2006;114:201-208.
32. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, Antman EM, Braunwald E. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J 2004;25:1998-2005.
33. Pitsavos C, Kourlaba G, Panagiotakos DB, Kogias Y, Mantas Y, Chrysohoou C, Stefanadis C. Association of creatinine clearance and in-hospital mortality in patients with acute coronary syndromes: the GREECS study. Circ J 2007;71:9-14.
34. Schiele F, Legalery P, Didier K, Meneveau N, Seronde MF, Caulfield F, Ducloux D, Bechetoille P, Magnin D, Faivre R, Bassand JP. Impact of renal dysfunction on 1-year mortality after acute myocardial infarction. Am Heart J 2006;151:661-667.
35. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004;351:1285- 1295.
36. Baumelou A, Bruckert E, Bagnis C, Deray G. Renal disease in cardiovascular disorders: an underrecognized problem. Am J Nephrol 2005;25:95-105.
37. Han JH, Chandra A, Mulgund J, Roe MT, Peterson ED, Szczech LA, Patel U, Ohman EM, Lindsell CJ, Gibler WB. Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes. Am J Med 2006;119:248-254.
38. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1-12.
39. Khatami Z, Handley G, Narayanan K, Weaver JU. Applicability of estimated glomerular filtration rate in stratifying chronic kidney disease. Scand J Clin Lab Invest 2007;67:297-305.
40. Herget-Rosenthal S, Bokenkamp A, Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 2007;40:153-161.